| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $15,324,053 ) |
| | 2025 | 2025 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | 2B2CMS331786 | Integrated Care for Kids (InCK) | 01 | 6 | CMS | 5/2/2025 | $0 |
| | 2025 | 2025 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01NS133233 | Neutrophil extracellular traps and associated pathogenesis in TBI: a novel peptide therapeutic strategy. | 000 | 2 | NIH | 2/20/2025 | $398,475 |
| | 2025 | 2025 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01CA270252 | Identifying and characterizing functional noncoding mutations in multiple myeloma | 001 | 3 | NIH | 5/22/2025 | $70,603 |
| | 2025 | 2025 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01CA270252 | Identifying and characterizing functional noncoding mutations in multiple myeloma | 000 | 3 | NIH | 3/19/2025 | $635,423 |
| | 2025 | 2025 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | UH3OD035546 | Enriching ECHO Cohorts with High-risk Pregnancies and Children with Health Challenges (Enriching ECHO) | 000 | 3 | NIH | 6/5/2025 | $5,019,949 |
| | 2025 | 2025 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R21AI190958 | Effects of antifungal drug treatment and immune dysfunction on the evolutionary dynamics of gut-colonizing Candida glabrata | 000 | 1 | NIH | 1/27/2025 | $265,650 |
| | 2025 | 2025 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01AI112579 | Regulation of T cell exhaustion via 3D chromatin architecture | 000 | 10 | NIH | 1/28/2025 | $624,855 |
| | 2025 | 2025 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01CA290808 | ID3 regulation of tissue-infiltrating T cells mediating graft-versus-host disease and leukemia rejection | 000 | 2 | NIH | 4/8/2025 | $660,200 |
| | 2025 | 2025 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01CA290808 | ID3 regulation of tissue-infiltrating T cells mediating graft-versus-host disease and leukemia rejection | 001 | 2 | NIH | 5/28/2025 | $73,355 |
| | 2025 | 2025 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | H79TI083671 | HMH Youth and Family TREE Program | 002 | 3 | SAMHSA | 6/27/2025 | $58,815 |
| | 2025 | 2025 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01AI177342 | Optimization of rifamycins to overcome intrinsic resistance of nontuberculous mycobacteria to improve treatment of NTM lung disease | 000 | 3 | NIH | 5/28/2025 | $838,280 |
| | 2025 | 2025 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01AI132374 | Discovery of novel lead-target pairs and identification of all-oral bactericidal drug regimens for Mycobacterium abscessus lung disease | 001 | 8 | NIH | 4/11/2025 | $872,777 |
| | 2025 | 2025 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R37CA250661 | Harnessing the thymus for long-term tumor control with hematopoietic stem cell-derived naive CAR T cells | 001 | 4 | NIH | 6/3/2025 | $53,945 |
| | 2025 | 2025 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R37CA250661 | Harnessing the thymus for long-term tumor control with hematopoietic stem cell-derived naive CAR T cells | 000 | 4 | NIH | 1/7/2025 | $485,503 |
| | 2025 | 2025 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01AI182977 | Tissue specific immunity to fungal infections | 000 | 1 | NIH | 11/22/2024 | $857,215 |
| | 2025 | 2025 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R21AI187674 | C25-modified rifabutin analogs as a novel medicinal chemistry strategy to overcome drug-resistant tuberculosis | 000 | 1 | NIH | 11/13/2024 | $265,650 |
| | 2025 | 2025 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01AI184502 | Shorter and more effective oral regimens for M. abscessus pulmonary disease | 000 | 1 | NIH | 1/21/2025 | $895,538 |
| | 2025 | 2025 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01CA254274 | Study of the IL-33-driven immune cell organization underpinning responses to immune checkpoint blockade cancer therapy | 000 | 6 | NIH | 4/30/2025 | $361,003 |
| | 2025 | 2025 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01CA254274 | Study of the IL-33-driven immune cell organization underpinning responses to immune checkpoint blockade cancer therapy | 001 | 6 | NIH | 5/23/2025 | $40,110 |
| | 2025 | 2025 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01AI141805 | Dissecting the molecular targets to overcome beta-lactam resistance in M. abscessus complex | 001 | 5 | NIH | 6/4/2025 | $901,706 |
| | 2025 | 2025 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | 2B2CMS331786 | Integrated Care for Kids (InCK) | 00 | 6 | CMS | 12/16/2024 | $2,000,000 |
| | 2025 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | UG3OD035546 | Enriching ECHO Cohorts with High-risk Pregnancies and Children with Disabilities (Enriching ECHO) | 000 | 2 | NIH | 12/23/2024 | $0 |
| | 2025 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | H79TI083671 | HMH Youth and Family TREE Program | 001 | 2 | SAMHSA | 5/14/2025 | $0 |
| | 2025 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | H79TI083671 | HMH Youth and Family TREE Program | 000 | 2 | SAMHSA | 3/26/2025 | $0 |
| | 2025 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | K22CA288932 | Cancer Misinformation and Use of Complementary and Alternative Therapy (CAM) among Patients with Cancer. | 000 | 1 | NIH | 4/4/2025 | $0 |
| | 2025 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | H79TI084385 | I.C.A.R.E. - Integrated Care for Addiction Recovery Expansion | 000 | 4 | SAMHSA | 4/22/2025 | $0 |
| | 2025 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | T2253418 | Dental Reimbursement Program | 01 | 1 | HRSA | 5/23/2025 | $0 |
| | 2025 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | 2B2CMS331786 | Integrated Care for Kids (InCK) | 06 | 5 | CMS | 10/29/2024 | $0 |
| | 2025 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | 2B2CMS331786 | Integrated Care for Kids (InCK) | 05 | 5 | CMS | 10/4/2024 | $0 |
| | 2025 | 2023 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01DE028961 | Dissecting cell composition and drug sensitivity in human adenoid cystic carcinomas (ACCs) | 001 | 6 | NIH | 2/19/2025 | $0 |
| | 2025 | 2023 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01CA283566 | Nuclear envelope and predisposition to hepatic neoplasia | 001 | 2 | NIH | 2/24/2025 | $8,532 |
| | 2025 | 2023 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | T2249945 | Dental Reimbursement Program | 01 | 1 | HRSA | 12/4/2024 | $0 |
| | 2025 | 2023 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01AI141183 | Novel bi-specific immunotherapeutic against high-threat Gram-negative pathogens | 000 | 5 | NIH | 2/28/2025 | $0 |
| | 2025 | 2022 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01AI141805 | Dissecting the molecular targets to overcome beta-lactam resistance in M. abscessus complex | 000 | 4 | NIH | 2/11/2025 | $0 |
| | 2025 | 2022 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | U19AI171401 | Metropolitan AntiViral Drug Accelerator | 001 | 1 | NIH | 4/7/2025 | $0 |
| | 2025 | 2022 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | U19AI171401 | Metropolitan AntiViral Drug Accelerator | 000 | 1 | NIH | 3/25/2025 | $0 |
| | 2025 | 2022 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01AI132374 | Discovery of novel lead-target pairs and identification of all-oral bactericidal drug regimens for Mycobacterium abscessus lung disease | 000 | 6 | NIH | 1/19/2025 | $0 |
| | 2025 | 2022 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01AI139874 | Ezh2 regulates follicular helper T cell differentiation | 000 | 6 | NIH | 2/10/2025 | $0 |
| | 2025 | 2022 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01AI138986 | Novel bi-specific immunoprophylactics against multi-drug resistant Gram-negativebacterial infections | 000 | 5 | NIH | 11/22/2024 | $0 |
| | 2025 | 2022 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | T1433114 | ANE - Nurse Practitioner Residency Program | 04 | 4 | HRSA | 11/13/2024 | -$63,531 |
| | 2025 | 2021 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01HD090180 | Epigenetics of Down Syndrome | 000 | 6 | NIH | 11/19/2024 | $0 |
| | 2025 | 2021 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01CA212639 | Targeting Transcriptional Co-repressor CoREST Complex in Melanoma | 000 | 5 | NIH | 11/25/2024 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $21,654,919 ) (Continued on the next page) |
| | 2024 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | 2B2CMS331786 | Integrated Care for Kids (InCK) | 03 | 5 | CMS | 6/14/2024 | $0 |
| | 2024 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01AI109025 | Critical Factors Influencing Echinocandin Resistance in Candidaglabrata | 001 | 12 | NIH | 7/2/2024 | $837,746 |
| | 2024 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01CA270252 | Identifying and characterizing functional noncoding mutations in multiple myeloma | 001 | 2 | NIH | 4/22/2024 | $36,996 |
| | 2024 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01CA270252 | Identifying and characterizing functional noncoding mutations in multiple myeloma | 002 | 2 | NIH | 5/10/2024 | -$32,188 |
| | 2024 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01CA270252 | Identifying and characterizing functional noncoding mutations in multiple myeloma | 000 | 2 | NIH | 3/13/2024 | $665,916 |
| | 2024 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01NS133233 | Neutrophil extracellular traps and associated pathogenesis in TBI: a novel peptide therapeutic strategy. | 000 | 1 | NIH | 3/5/2024 | $442,750 |
|
